Pygaba 75 Drug Interactions

Since pregabalin undergoes negligible metabolism in humans, pharmacokinetics of the drug are unlikely to be affected by other agents through metabolic interaction. In addition, pregabalin does not bind to plasma proteins, a pharmacokinetic interaction with drugs that are highly protein bound is unlikely.
Pharmacokinetic interaction unlikely with anticonvulsants (e.g., phenytoin, carbamazepine, valproate, lamotrigine, phenobarbital, topiramate). Concomitant administration of gabapentin with pregabalin did not alter pharmacokinetics of gabapentin although the rate, but not the extent, of absorption of pregabalin was decreased slightly. Tiagabine does not appear to effect the pharmacokinetics of pregabalin.
Glyburide, insulin and metformin do not appear to affect the pharmacokinetics of pregabalin. Potential pharmacologic interaction with thiazolidinediones (e.g., increased risk of weight gain and peripheral edema).
Pharmacokinetic interaction with lorazepam, oxycodone and alcohol is unlikely. Potential pharmacologic interaction (e.g., additive effects on cognitive and gross motor functioning); no clinically important effects on respiration.
Potential pharmacologic interaction with angiotensin-converting enzyme (ACE) inhibitiors (e.g., increased risk of developing angioedema).
Potential pharmacologic interaction (e.g., additive CNS depressant effects) with concurrent administration of CNS depressants, including opiates and benzodiazepines.
Pharmacokinetic interaction with oral contraceptives is unlikely.